Therapy Areas: Cardiovascular
Celyad Oncology sells C-Cathez catheter to CellProthera
12 February 2026 - Biotechnology company Celyad Oncology (Euronext Brussels:CYAD) announced on Thursday that it has sold its C-Cathez transendocardial catheter to CellProthera, including all intellect...
Realheart secures European patent for artificial heart technology
11 February 2026 - Artificial heart technology company Scandinavian Real Heart AB (Nasdaq Stockholm First North Growth Market:HEART) announced on Wednesday that it has received patent approval from th...
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
4 February 2026 - American specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) said on Wednesday it has received Fast Track Designation from the US Food and Drug Administra...
Boehringer Ingelheim's VETMEDIN gains US FDA approval to delay congestive heart failure onset in dogs
20 January 2026 - German biopharmaceutical company Boehringer Ingelheim announced on Monday that the US Food and Drug Administration (FDA) has approved VETMEDIN (pimobendan) Chewable Tablets and VETME...
Myqorzo and Redemplo receive regulatory approval in China
15 January 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that China's National Medical Products Administration has approved two Sanofi-licen...
Cereno Scientific publishes first peer-reviewed data on CS014, highlighting antithrombotic efficacy without bleeding risk
14 January 2026 - Biotechnology company Cereno Scientific (Nasdaq First North: CRNO B) on Wednesday reported publication of the first peer-reviewed manuscript on its HDAC inhibitor CS014 in the Journa...